Twist Bioscience Corporation TWST R2KR3KPHARMA
Company Overview
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Why Investors Should Care
Revenue has grown at a 55.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.24.
Recent Developments
- Sep 2025 Revenue of $376.57M (+20.3% YoY); net profit $-77.67M.
- Trailing 12 Months Year-on-year growth — revenue +23.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 55.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 55.94% |
| 1 Year: | 23.20% |
Stock Price Performance
| 1 Year: | +331.97% |
| 6 Months: | +163.66% |
| 3 Months: | +78.79% |
| 1 Month: | +13.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)48.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 55.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TWST Twist Bioscience Corporation R2KR3KPHARMA | 123.76 | -55.50 | $7.76B | 0.00% | -24.75% | -29.59% | 55.94% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.31M | 6.17M | 6.54M | 11.49M | 13.56M | 13.60M | 17.16M | 19.30M | 21.21M | 28.16M | 31.20M | 35.02M | 42.02M | 48.13M | 56.11M | 54.24M | 60.18M | 63.74M | 71.50M | 75.30M | 81.46M | 88.71M | 92.79M | 96.06M | 103.70M | 110.72M | 118.38M |
| Operating Income | -16.75M | -16.62M | -17.49M | -22.90M | -26.26M | -28.12M | -55.83M | -32.09M | -28.20M | -32.79M | -38.00M | -42.12M | -55.94M | -60.80M | -61.16M | -44.63M | -61.64M | -60.78M | -46.98M | -48.89M | -88.92M | -34.64M | -41.56M | -30.12M | -32.90M | -45.86M | -36.28M |
| Net Income | -16.94M | -16.87M | -17.62M | -22.64M | -25.93M | -27.92M | -55.64M | -31.77M | -28.21M | -32.90M | -37.92M | -40.04M | -45.56M | -60.67M | -60.52M | -41.82M | -59.16M | -57.40M | -43.01M | -45.49M | -85.57M | -31.59M | -39.33M | 20.39M | -30.51M | -44.02M | -35.05M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.78 | -0.82 | -0.91 | -1.13 | -1.08 | -0.74 | -1.04 | -1.01 | -0.75 | -0.79 | -1.47 | -0.53 | -0.66 | 0.33 | -0.50 | -0.71 | -0.56 |
| R&D Expense | 4.30M | 4.71M | 5.27M | 7.27M | 8.91M | 9.01M | 10.30M | 10.63M | 10.44M | 14.00M | 15.79M | 19.84M | 22.63M | 31.23M | 36.84M | 31.24M | 27.38M | 24.53M | 23.10M | 24.15M | 22.47M | 21.31M | 23.92M | 18.05M | 17.13M | 19.70M | 18.02M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.77M | 25.43M | 54.38M | 90.10M | 132.33M | 203.56M | 245.11M | 312.97M | 376.57M |
| Operating Income | -58.48M | -70.56M | -108.85M | -140.08M | -152.73M | -234.78M | -217.16M | -220.83M | -136.26M |
| Net Income | -59.31M | -71.24M | -107.67M | -139.93M | -152.10M | -217.86M | -204.62M | -208.73M | -77.67M |
| Diluted EPS | - | - | - | -3.57 | -3.15 | -4.04 | -3.60 | -3.60 | -1.30 |
| R&D Expense | 19.17M | 20.35M | 35.68M | 43.01M | 69.07M | 120.31M | 106.89M | 90.85M | 80.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 115.79M | 186.99M | 398.88M | 702.10M | 961.38M | 776.40M | 614.32M | 641.86M |
| Total Equity | -76.61M | -133.36M | -201.42M | 152.08M | 336.26M | 580.82M | 789.38M | 623.43M | 472.69M | 472.96M |
| Cash & Equivalents | - | 31.23M | 80.76M | 46.73M | 93.67M | 465.83M | 378.69M | 286.47M | 226.32M | 183.05M |
| Long Term Debt | - | - | 7.22M | 4.40M | 1.40M | - | - | - | - | - |
| Total Liabilities | - | - | 26.73M | 34.91M | 62.62M | 121.28M | 171.99M | 152.97M | 141.63M | 168.90M |
| Current Liabilities | - | - | 18.54M | 30.35M | 36.03M | 63.05M | 90.66M | 73.32M | 71.01M | 91.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -51.30M | -66.16M | -87.94M | -142.25M | -112.24M | -124.39M | -142.47M | -64.09M | -47.63M |
| Investing Cash Flow | -9.99M | 27.31M | -104.81M | -114.65M | 156.16M | -232.93M | 50.61M | -3.07M | -24.76M |
| Financing Cash Flow | 63.80M | 88.82M | 158.58M | 303.73M | 329.18M | 270.53M | 911.00K | 6.89M | 28.54M |
| Capital Expenditure | -6.59M | -3.69M | -14.76M | -9.87M | -27.06M | -101.86M | -27.78M | -5.08M | -28.00M |
| Free Cash Flow | -57.90M | -69.85M | -102.69M | -152.12M | -139.31M | -226.24M | -170.25M | -69.17M | -75.63M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -543.2% | -277.5% | -200.1% | -155.5% | -115.4% | -115.3% | -88.6% | -70.6% | -36.2% |
| Net Margin % | -550.8% | -280.2% | -198.0% | -155.3% | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% |
| ROE % | 44.5% | 35.4% | -70.8% | -41.6% | -26.2% | -27.6% | -32.8% | -44.2% | -16.4% |
| ROCE % | - | -72.6% | -69.5% | -38.6% | -23.9% | -27.0% | -30.9% | -40.6% | -24.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.30% | 5.83M | $824.80M |
| 2 | Artisan Partners Limited Partnership | 7.66% | 4.80M | $678.91M |
| 3 | FMR, LLC | 7.50% | 4.70M | $664.92M |
| 4 | ARK Investment Management, LLC | 7.26% | 4.55M | $643.25M |
| 5 | Price (T.Rowe) Associates Inc | 5.80% | 3.63M | $513.87M |
| 6 | State Street Corporation | 5.15% | 3.23M | $457.02M |
| 7 | Vanguard Portfolio Management LLC | 4.51% | 2.82M | $399.40M |
| 8 | Vanguard Capital Management LLC | 4.30% | 2.70M | $381.62M |
| 9 | Edgepoint Investment Group Inc. | 4.02% | 2.52M | $356.51M |
| 10 | William Blair Investment Management, LLC | 3.47% | 2.17M | $307.44M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TWST
Twist Bioscience Stock: 6 Straight Red Days, Down 19% - Trefis
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPdVlaLVkxaVU3dTloUGlJTWdOYklzYi1GeDA3TFhrdm81Zk5udHdxNTlTemVUeUNUOWd1djBzbUlGeFRUZzdhdjNod2o3X05TTVdlZXQzSUxadUtZYkxBTFU5b0loaklCN2U4czJtcG9ZUzUxdXJrQ0F6RDN1bjNodGJCVzlBakhsdnVWbX…
About Twist Bioscience Corporation • Robinhood Token - Coinbase
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNTHlHd1Zqbl96ZmstM3VsOEJsQkdpX2lQX0ZiM1FDUTA0c3A3blNEUEZyNUVZWHFCTHFKU0ItQ2xhT2pDaEdfRFpCU0ZRVTNGc1JIZHRFMmNvOXViZk5EdU1LNG1HN1h4N1B0SExzNE9aU2ZCdk1wWU9neFlzck0zRDBJbV9ZSzJZ?oc=5"…
Twist Bioscience (TWST) Stock Looks Overvalued Even With Strong Growth Hopes - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQa0hoMGg5RHJRLURSbURQODM5Z1k0a25ZeWlnNHZSTlNmZl8takpUMmJsS3Z5dGljV3ZXTkotVFBZSzVlV2tjdzNva2x2WFVKX1N4RGxOdEl3R205aUVkNkxCYmVzbllIaFZRcDdMQ2JlM3RCUW9jU0FibG12LVZxcklDczhqb3UxOGNJcU…
Twist Bioscience Corp (TWST) Shares Fall 3.0% -- What GF Score o - GuruFocus
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQR3A4VGszSGUyekh1Sm9SUEI4MVR0VWFycDlEMTIxbmU5cy0xODVCZTFVWEtqLVA4OE5BT3VraDZTQlFWTU5FWUtmaE1WdHFFUjhUMkhfZ3ZZbmJiOGhrdVZZSm5CS2RPQ09vdU8ydm53emhESWdIbDh2NHlnbTNIQTlodW42STRNaURqdj…
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now) (NASDAQ:TWST) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNSXltdUE4Uml4RUhWUHJURjZvS0FQc2wzeGd5VFNaTVRZdHhvWkdHQ0R0eDdTWXdscU83R0d4bVdQQ0NxUS1GblZ1SW1TU3dlSHJNMDFrX3lTQ2c3eGFrXzJZaTRaaHI5UjdJUnltbFBydjlPVkwycTJPVWFIMEgwbURESlM3RmVjaUIyUz…
Three Noteworthy Biotechs Just Reported Earnings — And Only One Recovered - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQd2FTcUhYdzZkLVA3Y2tnNE9pRWRubDkzN1hVeEVFZ0pZYlcyX0didmx0UmZQbnZMTGotSEJvY3RHeVJPWVVZT3VQUGJkQWdFVUo0aFZGMVJXRi1RSktqUlpERWJjSTJMY1NPblpIaHpGRGVLeGttYVRuRW1lWC1Cd3lkQ3BURF85d0QtNk…
TWST — Frequently Asked Questions
What is the current share price of Twist Bioscience Corporation (TWST)?
As of 2026-09-07 16:24 PDT, Twist Bioscience Corporation (TWST) trades at $123.76 on NasdaqGS. Its 52-week range is $24.16 to $153.10.
What is the market capitalisation of TWST?
Twist Bioscience Corporation (TWST) has a market capitalisation of $7.76B on NasdaqGS.
What is the P/E ratio of TWST?
TWST trades at a trailing price-to-earnings (P/E) ratio of -55.50. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 15.80.
What is the return on equity (ROE) of TWST?
TWST has a return on equity (ROE) of -29.59%. Its return on capital employed (ROCE) is -24.75%.
Is TWST a good stock to buy?
This page provides a data-driven analysis of Twist Bioscience Corporation (TWST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.